NCT07551440Recruiting
Identification of Therapeutic Targets in Metastatic Gastric Cancer
Identification of Novel Therapeutic Targets in Gastric Cancer With Lymph Node or Distant Metastasis: An Explorative Study
Source: ClinicalTrials.gov · Last updated 24 Apr 2026
Brief summary (registry, in English)
This is a pilot study aiming at identifying novel therapeutic molecular targets in patients with gastric cancer with lymph nodes or distant metastasis. All patients who are diagnosed with gastric cancer with metastases in the Prince of Wales Hospital will be screened for eligibility.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 10 Aug 2023
- Start date
- 15 Oct 2023
- Primary completion date
- Apr 2033
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07551440
What you commit to
- Study type: Observational
- Planned participants: 100
- From 15 Oct 2023 to the primary completion date, Apr 2033
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient who will not be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy
Other illness
- Patients with irreversible coagulation disorders
Other
- Pregnancy or breastfeeding
Who the study is looking for
- Patients age \>= 18, \<= 80 years old
- Performance status (WHO) \<=2
- Gastric adenocarcinoma with lymph node metastasis or distant metastasis such as liver metastases, lung metastases, bone metastases, peritoneum metastases
- Patients with isolated ovarian metastasis could be included
- Patients who will be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy
- Ability to give written consent before the commencement of treatment
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Chinese University of Hong Kong Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.